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Ten years ago, in 1955 the "Met-
abolic Establishment" first began to 
hear what might be called the 
"Great Diabetes Paradox:" im-
paired glucose tolerance can occur 
side by side with normal concen-
trations of blood insulin or insulin-
like activity. This sounded like en-
docrinologic heresy but it has been 
confirmed by almost every worker 
in the field, using different assay 
methods. Since the paradox is true, 
it is provocative, for it suggests 
that an important truth may be 
hidden beyond it. 
One line of approach to this 
problem has been to look for in-
sulin antagonists which might pre-
vent normal amounts of insulin 
from accomplishing their physio-
logical tasks. Much work has been 
done in this area, some of it con-
troversial, all of it exciting. It is not 
easy to prepare a critical evaluation 
without beginning to seem to be 
against progress. But true progress 
requires that controversy be re-
solved. 
INSULIN ANTAGONISTS 
In 1954, John Vallance-Owen 
and Barbara Hurlock described a 
method for the assay of insulin-like 
activity (ILA) in plasma, using as 
an index of response the amount 
of glucose disappearing from the 
medium in which was incubated a 
rat hemi-diaphragm. These workers 
found a low level of ILA in fasting 
normals, with a brisk rise after glu-
cose ingestion. Crystalline beef in-
sulin added to plasma was recovered 
quantitatively. 
The next year Vallance-Owen 
and co-workers ( 1955) reported 
similar values in obese diabetics re-
quiring no drug treatment. but 
found no detectable ILA in the 
plasma of uncontrolled, insulin-
requiring diabetics; crystalline in-
sulin added in vitro had little or no 
effect. Later these authors showed 
that if plasma from such patients 
were diluted 1 : 4, ILA could be 
again demonstrated and added in-
sulin recovered quantitatively. They 
concluded that such plasma con-
tained ILA all along, but that some 
other plasma component antagon-
ized the action of both the ILA 
and added crystalline insulin (Val-
lance-Owen et al., 1958a). It has 
never been clear why the antago-
nism disappears when both ILA and 
the antagonist are diluted to the 
same degree. 
The next step was to isolate and 
identify the antagonist (Vallance-
Owen et al., 1958b). Fractionation 
of serum proteins showed the an-
tagonist to be associated with al-
bumin and because it could be 
eluted off the albumin on column 
chromatography, it was called "syn-
albumin antagonist." Serum al-
bumin from both normal and dia-
betic patients antagonized 1,000 
µ.u per ml of beef insulin when 
added in a 3.5 to 5.5 % concentra-
tion to the medium containing rat 
hemi-diaphragm. When the same 
albumin fractions were added in 
only 1.25 % concentration, there 
was no inhibition with normal al-
bumin but persisting, almost com-
plete, inhibition with diabetic al-
bumin. A fair appraisal would be 
that everyone has synalbumin an-
tagonist, but that insulin-requiring 
diabetics have more of it than 
others. 
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Other disease entities were soon 
admitted to the not-so-exclusive 
ranks of synalbumin excess. In 
1961, obese maturity-onset dia-
betics and pre-diabetics with normal 
glucose tolerance were shown to 
have antagonist at the 1.25 % con-
centration in blood (Vallance-Owen 
and Lilley). In 1963, synalbumin 
antagonist was found in 19 of 28 
patients with fresh myocardial in-
farction and n_o family history of 
diabetes. This finding persisted after 
recovery from infarction, and con-
trasted with an incidence in only 
6 of 28 control patients without 
vascular disease or positive family 
history (Vallance-Owen and Ash-
ton). Then the antagonist was 
found to be present in 6 of 10 
grossly obese women without dia-
betic "chemistries" or family his-
tory (Vallance-Owen, 1965) . Fur-
ther, Alp and Recant (1965) have 
demonstrated the presence of synal-
bumin antagonist (at levels be-
tween 1.25 and 3.50%) in ten 
pregnant women in the third tri-
mester, again without family his-
tory of diabetes. 
EFFECT ON METABOLISM IN 
ADIPOSE TISSUE 
It was soon learned that synal-
bumin antagonist did not antago-
nize the effect of insulin on adipose 
tissue (Vallance-Owen and Lilley, 
1961 ; Lowy, Blanshard, and Phear, 
1961). Vallance-Owen has empha-
sized this (1964a, 1964b), and has 
speculated that obesity may be a 
manifestation of diabetes rather 
than the other way around. In-
vestigation of this phenomenon by 
Alp and Recant ( 1964) revealed 
that the synalbumin antagonist, like 
insulin, actually stimulated the oxi-
dation of glucose by adipose tissue. 
The similarity was particularly close 
in that anti-insulin antibody could 
abolish this effect, a finding con-
sidered by many to be proof of 
identity with insulin. Furthermore, 
the effect of crystalline insulin was 
enhanced by the presence of synal-
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bumin. Fourteen diabetic albumin 
samples in 1.25 % concentration 
produce on the average 86% inhibi-
tion of the effect of 1000 µ,u per ml 
of insulin on rat diaphragm. The 
same albumin contributed on the 
average 41 % of the stimulation of 
glucose uptake by adipose tissue 
which was ascribed to insulin-like 
activity. It is perfectly clear that 
such a metabolic picket line could 
divert a great deal of blood glucose 
away from muscle and into fat. 
These divergent actions have not 
been investigated by other work-
ers, who have concentrated their 
efforts on the study of the dia-
phragm effect. Sherman ( 1965) has 
recently reported confirmation of 
the findings of synalbumin antagon-
ist in normal and diabetic plasma 
in the same concentration as origi-
nally noted. Using the Stadie tech-
nique, Davidson and Goodner 
( 1965) found that after diaphragm 
was dipped in solution containing 
synalbumin antagonist, no amount 
of washing would enable it to re-
spond properly to insulin. Con-
versely, prior dipping in an insulin 
solution partially but not com-
pletely prevented subsequent action 
of the antagonist. They also found 
that a huge excess of insulin did not 
wholly overcome the effects of a 
small amount of synalbumin, and 
inferred that the inhibition is not 
competitive, contrary to the report 
of Alp and Recant (1 965) that it 
was partially competitive. Of spe-
cial interest was the finding that 
synalbumin also antagonized the 
insulin effect of intracellular ac-
cumulation of aminoisobutyric acid, 
and to a lesser degree of glycogen 
synthesis, which actually tended to 
increase proportionally as overall 
glucose utilization declined. Both 
antagonistic human serum albumin 
and non-antagonistic beef serum 
albumin depressed the incorpora-
tion of glycine-2-C14 into muscle 
protein. Davidson and Goodner 
concluded that the synalbumin an-
tagonist either binds strongly to the 
cell membrane, precluding contact 
with insulin, or irreversibly alters 
the membrane's biochemical re-
sponse to insulin. 
CHEMICAL IDENTITY OF 
ANTAGONIST 
During the last three years, Val-
lance-Owen and his colleagues have 
been attempting to identify synal-
bumin. Preliminary studies sug-
gested that it was probably a poly-
peptide. In 1963, Ensinck et al. 
found that when insulin is cleaved 
enzymatically in vitro, the 30-amino 
acid B chain appears to associate 
with albumin. Ensinck and Val-
lance-Owen ( 1963) reported at the 
same time that purified B chain 
readily unites with non-antagonistic 
albumin in vitro, and thereby re-
stores the usual antagonism to 
1000 µ,u per ml. They have dem-
onstrated 10 biochemical similari-
ties between isolated synalbumin 
antagonist and B chain, with no 
reported dissimilarities (Vallance-
Owen, 1964b). In 1964, Ensinck 
et al. incubated 1131-Iabelled insulin 
with the hepatic enzyme that cleaves 
insulin, glutathione-insulin transhy-
drogenase. They dialyzed the ma-
terial and found that most of the 
radioactivity remained attached to 
the albumin on electrophoresis. In 
1965, Ensinck, Mahler, and Val-
lance-Owen repeated this study 
with non-labelled insulin in order 
to test the effects of various alky-
lating agents. Reduced or sulfated 
B chain was antagonistic as usual, 
but if the molecule were oxidized, 
or its thiol groups alkylated with 
iodacetamide or N-ethylmaleimide, 
the antagonism disappeared. It is 
generally accepted that the insulin 
molecule attaches to a receptor site 
on the cell membrane by forming 
disulfide bonds. Reduced B chain, 
with its own "dangling" disulfide 
bonds, could conceivably attach to 
the cell membrane and effectively 
compete with insulin for attach-
ment sites by the mechanism of 
steric hindrance. Ensinck et al. 
(1965) have found that albumin-B 
chain complex incubated with dia-
phragm or cell-free muscle extracts 
2.5 
become non-antagonistic, so appar-
ently B chain has a greater affinity 
for cell membrane than for the 
albumin molecule. 
Vallance-Owen (1946b) has pre-
sented the idea that hepatic 
glutathione-insulin transhydrogen-
ase cleaves insulin to a greater or 
lesser extent corresponding to the 
activity of the pituitary-adrenal axis, 
but concedes that there is no direct 
support for this theory. As indirect 
support he cited earlier work on 
cats; ordinarily cats do not have 
the synalbumin antagonist (Val-
lance-Owen and Lukens, 1957), 
but, it can be demonstrated after 
pancreatectomy, although not after 
combined pancreatectomy and hy-
pophysectomy. 
ROLE IN PATHOGENESIS OF 
DIABETES 
The presumed role of synalbumin 
antagonist in the pathogenesis of 
diabetes mellitus can now be traced 
as follows: Due to a genetic predis-
position, there is excessive hepatic 
glutathione-insulin transhydrogen-
ase activity (perhaps due to de-
crease in inhibitor), which is exag-
gerated by pituitary-adrenal hyper-
activity. Insulin secreted by the pan-
creatic B cells reaches the liver via 
the portal vein and much of it there 
is cleaved to the A and B chains. 
The B chain binds to albumin, cir-
culates in the blood, and detaches 
from albumin at the cellular level 
in order to attach to membrane 
binding sites. In adipose tissue the 
B chain actively supports the up-
take of glucose; in muscle it merely 
inhibits the · attachment of the in-
tact insulin molecule. Therefore, 
glucose tolerance diminishes, blood 
sugar rises, the cells become ini-
tially hypersecretory and eventu-
ally exhausted, and permanent pan-
creatic diabetes ensues (Vallance-
Owen, 1964a and b). 
Vallance-Owen has been quite 
interested in using the presence of 
synalbumin antagonist as a bio-
chemical marker for the genetic 
diabetic predisposition ( 1964a) . 
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Most recently ( 1965), he studied 
94 people in 9 families. Of these 
38 had normal amounts of antago-
nist, and 56 had an increased 
amount equivalent to that found in 
diabetes ; 18 of these had frank 
diabetes, and 3 more had sponta-
neous hypoglycemia. He feels that 
the diabetic predisposition is in-
herited as a Mendelian dominant, 
that perhaps 25% of the world pop-
ulation is constituted as diabetic, 
but that probably only 10% of this 
segment will develop frank diabetes 
during life. 
CRITICISMS OF ROLE OF 
ANTAGONIST 
This review summarized a body 
of evidence assembled over a 
twelve-year period. On the other 
side of the argument, there is the 
following evidence: 
1) Berson and Yalow (1965) 
have challenged the experiment us-
ing l 1"1-labelled insulin and the he-
patic enzyme (Ensinck et al., 1964), 
on the grounds that the radioac-
tivity bound to albumin can occur 
without enzymatic intervention and 
probably represents damaged insulin 
as a result of irradiation. 
2) Some workers have found 
that albumin is not antagonistic to 
glucose uptake by muscle (Came-
ron, Keen, and Menzinger, 1964) 
or, if it is, only to an extent that 
could be explained by the associa-
tion of free fatty acids (Buse and 
Buse, 1964) . 
3) A more troublesome question 
is to explain the presence of synal-
bumin antagonist in pancreatecto-
mized animals who do not possess 
the antagonist in the intact state? 
Vallance-Owen (1964b) has ex-
plained this by saying that pre-
viously secreted insulin still circu-
lates and contributes B chain to 
form the antagonist. He argues that 
hypophysectomy prevents this by 
suppre8ising the activity of the he-
patic erzyme that cleaves insulin, 
a.nd th1tt administration of steroids 
reverses this suppression. It is diffi-
cult to understand how a metabolite 
of insulin could appear only after 
insulin production has been extin-
guished. 
4) One feels uneasy about the 
basic premise of this concept of 
diabetes; can we reasonably base 
our entire theory on the presence of 
a factor which can only be demon-
strated as something in human 
plasma which antagonizes the ef-
fects of beef insulin on rat dia-
phragm? This is several steps re-
moved from the clinical situati~n, 
and is subject to criticism since beef 
albumin does not antagonize beef 
insulin under these conditions 
(Davidson and Goodner, 1965). 
5) The same objection might be 
made to a specific pathogenetic role 
of an antagonist which occurs in 
such a large segment of the popu-
lation. If everyone possesses synal-
bumin antagonist, as demonstrated 
on rat diaphragm, and 25 % possess 
an excessive amount, why should 
only 2.5% ever develop even chem-
ical diabetes? Explaining this se-
lectivity is really not much easier 
then explaining the incidence of 
clinical diabetes without ever in-
voking synalbumin at all. A factor 
which is invoked to explain not 
only diabetes, but also myocardial 
infarction, obesity, and the third 
trimester of pregnancy does not 
really explain anything. 
6) Even if the synalbumin an-
tagonist were of metabolic impor-
tance to man, how would its excess 
lead to diabetes? According to Alp 
and Recant (1964, 1965), the in-
creased glucose uptake by adipose 
tissue ought to help counteract the 
decreased uptake by muscle, espe-
cially as the bulk of adiposity in-
creases. If so, should not progressive 
obesity lead to progressive improve-
ment in glucose tolerance? And in 
that case, why should cell secretion 
become exhau~ted? On this point 
the theory does not agree with 
clinical facts. 
7) Berson (1965) has recently 
quoted Mirsky as showing that con-
tinuous intravenous infusion of re-
duced B chain in dogs had no effect 
on glucose tolerance. 
CONCLUSION 
In conclusion, the synalbumin 
antagonist exists, and may be im-
portant in the pathogenesis of hu-
man diabetes, but its role has not 
been proved. The proof will require 
elucidation of the problem of spe-
cies specificity, and ability to meas-
ure accurately the levels of synal-
bumin antagonist. 
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